# Real World Evidence of the Efficacy and Safety of FOQUEST

> **NCT04152629** · PHASE4 · COMPLETED · sponsor: **Purdue Pharma, Canada** · enrollment: 257 (actual)

## Conditions studied

- Attention Deficit-Hyperactivity Disorder

## Interventions

- **DRUG:** Methylphenidate Hydrochloride
- **DRUG:** Lisdexamfetamine Dimesylate

## Key facts

- **NCT ID:** NCT04152629
- **Lead sponsor:** Purdue Pharma, Canada
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2019-09-19
- **Primary completion:** 2021-07-09
- **Final completion:** 2021-07-09
- **Target enrollment:** 257 (ACTUAL)
- **Last updated:** 2021-09-16


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04152629

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04152629, "Real World Evidence of the Efficacy and Safety of FOQUEST". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT04152629. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*